The authors of this review assess the role of endoscopic retrograde cholangiopancreatography (ERCP) and emerging endoscopic techniques in the diagnosis, treatment, and management of primary sclerosing ...

Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) both damage bile ducts and can cause bile buildup, inflammation, and scarring in the liver. PBC mainly affects small bile ...

Primary biliary cholangitis is a rare, chronic cholestatic liver disease characterized by the destruction of interlobular bile ducts, leading to cholestasis and liver fibrosis. Whether elafibranor, an ...

Effective treatments for patients with primary biliary cholangitis are limited. Seladelpar, a peroxisome proliferator–activated receptor delta agonist, has potential benefits. In this phase 3, ...

An international clinical trial involving UC Davis Health suggests the investigational drug Elafibranor is a potential novel treatment for patients with the rare, autoimmune disease primary biliary ...

Primary biliary cholangitis (PBC) has typically been considered a rare condition, with a pooled global estimated incidence of two per 100,000 people per year and an estimated prevalence of 15 per ...

Primary biliary cholangitis (PBC) is a rare autoimmune disease affecting the bile ducts in the liver. When bile ducts become damaged, bile can build up in the liver, leading to inflammation and ...

Sclerosing cholangitis and primary biliary cirrhosis, which is now called primary biliary cholangitis (PBC), are chronic cholestatic liver diseases, but they differ in their causes, affected bile ...